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Abstract The effect of the protein kinase C activator, phorbol 
12-myristate 13-acetate (PMA), on the metabolism of exogenous 
leukotriene (LT)A4 in human granulocytes was investigated. 
After incubation with LTA4 decreased levels of LTC4 but not 
LTB4 were observed in granuloeyte suspensions pretreated with 
PMA. This finding could in part be ascribed to oxidative metab- 
olism of LTC4, since PMA induced a rapid degradation of ex- 
ogenously added LTC 4. After blocking of LTC 4 metabolism with 
the H202 scavenger eatalase, a PMA-provoked suppression of 
the conversion of LTA 4 to LTC4 was observed, indicating PKC- 
dependent regulation of LTC4 synthase activity. This effect, as 
well as PMA-induced degradation of LTC 4 was prevented by 
specific protein kinase C inhibitors. 
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I. Introduction 
During cell activation leukotriene (LT) biosynthesis  initi- 
ated by liberation of arachidonic acid from membrane 
phospholipids through the action of a specific high molecular 
weight cytosolic phospholipase A2 (cPLA2) [1]. Subsequently, 
the fatty acid is transformed to the unstable poxide LTA4. The 
latter reaction is catalyzed by the 5-1ipoxygenase (5-LO), an 
enzyme operating in concert with a 5-1ipoxygenase activating 
protein (FLAP), which makes arachidonic acid available for 
enzymatic onversion [2]. 
The capacity to produce LTA 4 from endogenous substrate 
is a common feature among cells ofmyeloid origin. In contrast, 
the expression of enzymes capable of metabolizing this interme- 
diate differs between eutrophils, which utilise LTA 4 hydrolase 
to produce the leukocyte activator LTB4 [3], and eosinophils/ 
basophils whitch make use of LTC4 synthase, conjugating 
LTA 4 with reduced glutathione, to synthesise LTC4 [4,5]. In 
accordance, northern blot analysis demonstrated mRNA cod- 
ing for LTC4 synthase in human eosinophils, but not in neutro- 
phils [6]. Furthermore, monocytes/macrophages express both 
LTA4 hydrolase and LTC4 synthase activities [7,8]. Human 
platelets are devoid of 5-LO activity, but possess LTC 4 synthase 
activity [9,10], which enables them to produce LTC4 when sup- 
plied with LTA4 from surrounding cells, e.g. activated gran- 
ulocytes or monocytes [11]. 
Leukotriene C4 may be enzymatically transformed to the 
likewise biologically active metabolites LTD4 and LTE4 [12]. 
These three cysteinyl leukotrienes are powerful inflammatory 
mediators involved in allergy and asthma. Alternatively, LTC 4 
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may be rapidly inactivated by myeloperoxidase-dependent oxi- 
dative metabolism [13,14]. 
Leukotriene Ca synthase has been purified from guinea pig 
and human lung tissue [8,15] as well as from various cell lines, 
including established myeloid cells [16--18] and human 
erythroleukemia cells [19], and was found to be an 18 kDa 
polypeptide active as a homodimer. The enzyme was recently 
cloned and the deduced amino acid sequence demonstrated to 
be similar to FLAP, but not to any known cytosolic or micro- 
somal glutathione S-transferase [6,20]. The presence of LTC 4 
synthase in human lung tissue, alveolar macrophages, eosino- 
phils and platelets was recently demonstrated, using a polyclo- 
nal antibody against he enzyme [8]. 
It has recently been reported that the activity of LTC4 syn- 
thase in myeloid cells can be controlled via phosphoregulatory 
mechanisms. Thus, phorbol 12-myristate 13-acetate (PMA) 
provoked suppression of ionophore A23187- or LTA4-induced 
LTC4 formation in established human pre-leukemic cell lines 
[21,22]. Similarly, LTC4 synthase activity in human platelets has 
been demonstrated to be phosphoregulated viaboth PKC-de- 
pendent and receptor-mediated, PKC-independent mecha- 
nisms [23]. It was therefore of interest o investigate whether 
LTC 4 formation in normal human granulocytes is governed via 
similar mechanisms. The present findings demonstrate hat ac- 
tivation of PKC in granulocytes lowers the levels of LTC4, not 
only via stimulation of oxidative LTC4 degradation, but also 
via inhibition of LTC4 synthase activity. 
2. Experimental 
2.1. Materials 
Leukot r ienes  B 4 and C 4 and 4fl-phorbol 12-myristate 13-acetate 
(PMA) were obtained from Biomol Research Laboratories (Plymouth 
Meeting, PA, USA). Ro 31-8220 was a kind gift from Dr. Trevor J 
Hallam, Roche Research Centre, Herts, UK. Catalase (from bovine 
liver, 65.000 units/mg) and GF 109203X were obtained from Calbio- 
chem-Boehring (La Jolla, CA, USA). o-Glucose, gluthatione and fatty 
acid-free human serum albumin were purchased from Sigma (St. Louis, 
MO, USA). Lymphoprep was from Nycomed Pharma AS (Oslo, Nor- 
way). Leukotriene Aa-methyl ester was a generous gift from Dr. Robert 
Zipkin, Biomol Research Laboratories, and was saponified as de- 
scribed [23]. 
2.2. Preparation of granulocyte suspensions and sonicates 
Peripheral blood from healthy volunteers who had not taken any 
medication for at least 10 days was collected in EDTA-containing 
Vacutainer blood collection tubes (Becton Dickinson, Rutherford, NJ, 
USA). After centrifugation at 200 x g for 15 min, the platelet-rich 
plasma was removed and the granulocytes were isolated from the re- 
maining lower phase by dextran sedimentation, hypotonic ammonium 
chloride lysis and Lymphoprep centrifugation [24]. The pellet (contain- 
ing > 98% granulocytes) was resuspended in phosphate-buffered saline 
(PBS, with 0.9 mM calcium chloride and 5 mM o-glucose, pH 7.4) at 
a concentration f 15 × 10 6 cells/ml. Platelet contamination was less 
than 0.5 platelet per granulocyte, as determined by phase-contrast 
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microscopy after lysis of the granulocytes. Granulocyte sonicates were 
prepared by sonication of cell suspensions upplemented with 3 mM 
glutathione (using an Ultrasonic disintegrator Mk2, Sussex, UK; power 
output: 50-150 W) at 0°C for 15 s. 
2.3. Incubation procedure 
Cell suspensions (0.5 1.0 ml) with or without catalase (60#g/ml) were 
equilibrated at37°C for 5 rain in the presence of human serum albumin 
(0.3 rng/ml). Thereafter the cells were incubated for 2-60 min in the 
absence or presence of PMA (5-160 nM). In some experiments the cells 
were incubated for 2 min with or without Ro 31-8220 (3 #M) or GF 
109203X (3 #M) prior to PMA treatment. Incubations were followed 
by determination f leukotriene metabolism as described below. 
2.4. Determination f leukotriene metabolism 
The metabolism of LTA4 in human granulocytes was determined by 
incubation with LTA4 (10/tM) at 37°C for 5 min (cell suspensions) or 
2.5 min (granulocyte sonicates). The ability to metabolize LTC4 was 
investigated by incubation of intact cells with LTC4 (600 nM) for 5 min 
at 37°C. Reactions were stopped by addition of five volumes of ethanol 
containing prostaglandin B2 as internal standard. After centrifugation 
and evaporation ofthe samples, leukotrienes were analyzed by reversed 
phase HPLC, using a Nova-Pak C18 column (3.9 x 150 ram, Waters 
Ass., Milford, MA, USA), eluted with acetonitrile/methanol/water/ 
acetic acid (27:18:54:0.8, v/v, apparent pH 5.6) at a flow rate of 
1.0 ml/min, and a variable wavelength UV-detector (LDC Spectromo- 
nitor III) connected to an integrator (LDC/Milton Roy CI-4000). 
3. Results 
3.1. Effect of phorbol ester on LTC 4 metabolism in human 
granuloeyte suspensions 
Addition of PMA to human granulocyte suspensions pro- 
voked a rapid oxidative metabolism of exogenous LTC4 in 
agreement with earlier findings [13,14]. Thus, after 5 rain. ap- 
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Fig. 1. Effect of PMA on the metabolism of exogenous LTC 4 in human 
granulocytes. Human granulocyte suspensions (15 x 10  6 cells/ml) con- 
taining human serum albumin (0.3 mg/ml) were equilibrated with (black 
bars) or without (white bars) catalase (60 ,ug/ml) at 37°C for 5 min and 
preincubated in the absence (control) or presence of PMA (80 nM) for 
another 2min or 20 min. Thereafter the cells were incubated with LTC4 
(600 nM) for 5 min. Each value represent the mean _+ S.D. of 3-5 
experiments performed in duplicate. Statistical nalysis was performed 
using Student's t-test for paired samples, n.s.: not significant; *P < 0.05 
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Fig. 2. Effect of PMA on LTC 4 levels in human granulocytes after 
addition of exogenous LTA4. Human granulocyte suspensions (15 x l0  6 
cells/ml) containing human serum albumin (0.3 mg/ml) were equili- 
brated with (black bars) or without (white bars) catalase (60 pg/ml) at 
37°C for 5 min and preincubated in the absence (control) or presence 
of PMA (80 nM) for another 2min or 20 min. Thereafter the cells were 
incubated with ETA 4 (10pM) for 5 min. Each value represent the mean 
+ S.D. of 3~1 experiments performed in duplicate. Statistical analysis 
was performed using Student's t-test for paired samples (PMA with or 
without catalase versus control with or without catalase respectively). 
n.s.: not significant; *P < 0.05; **P < 0.01. 
proximately 40% of added LTC 4 was recovered from granulo- 
cyte suspensions which had been preincubated with PMA for 
2 or 20 min, respectively (Fig. 1). The disappearance of LTC4 
was accompanied by the appearence of six new HPLC-peaks, 
including 6-trans-LTB4 isomers and LTC 4 sulphoxides (results 
not shown), in correspondence with previously reported oxida- 
tive metabolism of LTC 4 [13,14]. The metabolism could be 
inhibited by the H202 scavenger catalase (Fig. 1). No degrada- 
tion of LTC 4 was found in unstimulated control suspensions 
and conversion of LTC 4 to LTD 4 and LTE4 was not observed 
neither in control suspensions nor in the PMA-treated samples 
(results not shown). 
3.2. Effect of phorbol ester pretreatment on the levels of LTC 4 
and LTB 4 after incubation of human granulocyte 
suspensions with exogenous LTA 4 
The effect of PMA on the conversion of exogenous LTA 4 in 
human granulocyte suspensions was studied. Catalase was used 
in these experiments, in order to avoid the influence of oxida- 
tive LTC 4 metabolism. The capacity to transform LTA 4 to 
LTC 4 and LTB 4 in untreated control suspensions was reflected 
by the production of 212 + 56 pmol LTC4/ml (mean + S.D.; 
n = 6) and 451 + 103 pmol LTBJml  (mean + S.D.; n = 6), to- 
gether with minor amounts of the LTB 4 metabolites, 20-OH 
LTB 4 and 20-COOH LTB4 (results not shown). Measurable 
amounts of LTD4 or LTE4 were not detected. The basal conver- 
sion of LTA 4 to LTC 4 and LTB 4 was not affected by addition 
of catalase. Treatment of the cells with PMA (80 nM) in the 
absence of catalase for 2 or 20 min before addition of LTA4 led 
to decreased levels of LTC4, as compared to those obtained in 
control suspensions (Fig. 2). Addition of catalase totally re- 
versed the short-time, but not the long-time inhibitory effect of 
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Fig. 3. Time course of the effect of PMA on LTC4 synthase activity in 
human granulocytes. Human granulocyte suspensions (15 x 10 6 cells/ 
ml) containing catalase (60 pg/ml) and human serum albumin (0.3 
mg/ml) were equilibrated at 37°C for 5 min and preincubated in the 
absence (control) or presence of PMA (80 nM) for another 5 60 min 
prior to incubation with LTA4 (10/tM) for 5 rain. Each value represent 
the mean + S.D. of 34  experiments performed in duplicate. Statistical 
analysis was performed using Student's t-test for paired samples, n.s.: 
not significant; *P < 0.05; **P < 0.01; ***P < 0.001. 
PMA on LTC4 levels. The levels of LTB4 was unaffected by the 
phorbol ester (results not shown). Measurable amounts of leu- 
kotrienes could not be detected after treatment of granulocyte 
suspensions with PMA (160 nM) in the absence of LTA4 (re- 
sults not shown). 
3.3. Characterization of PMA-induced supression of LTC4 
synthase activity in human granulocytes 
The effect of PMA on LTC 4 synthase activity in granulocyte 
suspensions was characterized by determination of LTC 4 for- 
mation from exogenous ETA 4 in the presence of catalase. Time- 
course studies demonstrated a significant inhibitory effect of 
PMA (80 nM) on LTC4 synthase activity after 10 rain, with 
Table 1 
Effect of PMA on the formation of LTC 4 and LTB 4 from exogenous 
LTA4 in human granulocyte sonicates 
LTC4 (pmol/ml) LTB4 (pmol/ml) 
Control 684 + 228 729 + 150 
PMA 394 _+ 221" 654 + 117 
Human granulocyte suspensions (15 × 106 cells/ml) containing catalase 
(60/zg/ml) and human serum albumin (0.3 mg/ml) were equilibrated at
37°C for 5 min and preincubated in the absence (control) or presence 
of PMA (80 nM) for 30 min. Thereafter glutathione (3mM) was added 
and the cells were disrupted by sonication at 0°C for 15 s and immedi- 
ately preincubated at 37°C for 30 s prior to incubation with ETA 4 (10 
#M) for 2.5 min. Each value represent the mean + S.D. of 3 separate 
experiments performed in duplicate. Statistical analysis was performed 
using Student's t-test for paired samples. *P < 0.05. 
maximal suppression after 30 min (Fig. 3). In dose-response 
studies granulocyte suspensions were pretreated with PMA (5- 
160 nM) for 30 min (Fig. 4), A siginificant inhibitory effect was 
observed already at 10 nM and maximal inhibition was 
achieved at about 40-100 riM. 
Phorbol ester-induced inhibition of LTC 4 synthase activity 
was observed also in experiments where the granulocytes were 
disrupted by sonication in the presence of 3 mM glutathione, 
subsequent to incubation with or without PMA for 30 min. 
Thus, pretreatment with PMA provoked approximately 40% 
attenuation of the conversion of LTA 4 to LTC 4 in granulocyte 
sonicates (Table 1). In contrast, the production of LTB4 was 
unaffected by PMA. 
3.4. Reversal of P MA-induced effects on leukotriene metabolism 
by specific PKC inhibitors 
Preincubation of granulocyte suspensions with the specific 
protein kinase C inhibitors, Ro 31-8220 [25] or GF  109203X 
[26], reversed the inhibitory effect of PMA on granulocyte 
LTC 4 synthase activity and abolished PMA-induced oxidative 
LTC4 metabolism (Table 2). 
4. Discussion 
Direct activation of protein kinase C with nanomolar con- 
centrations of the phorbol ester PMA lowered the levels of 
LTC4 after incubation of human granulocyte suspensions with 
exogenous LTA4. This decrease was due to two distinct effects 
on leukotriene metabolism. Thus, PMA induced a rapid cata- 
lase-inhibitable degradation of exogenously added LTC4, in 
agreement with previous reports demonstrating myeloperoxi- 
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Fig. 4. Dose-response curve of the effect of PMA on LTC 4 synthase 
activity in human granulocytes. Human granulocyte suspensions 
(15 × 106 cells/ml) containing catalase (60 pg/ml) and human serum 
albumin (0.3 mg/ml) were equilibrated at37°C for 5 min and preincu- 
bated in the absence (control) or presence of PMA (5-160 nM) for 
another 30 min prior to incubation with LTA4 (10#M) for 5 min. Each 
value represent the mean + S.D. of 3 experiments performed in dupli- 
cate. 
90 M. Sj6linder et al./FEBS Letters 377 (1995) 87-91 
Table 2 
Reversal of PMA-induced effects on leuktriene metabolism in human 
granulocytes by PKC inhibitors 
A: LTC 4 degradation B: LTC4 synthase activity 
LTC4 (% of control) LTC4 (% of control) 
PMA 16 51 
PMA + Ro 31-8220 97 105 
PMA + GF 109203X 99 95 
Human granulocyte suspensions (15 × 10 6 cells/ml) containing human 
serum albumin (0.3 mg/ml) were equilibrated without (for determina- 
tion of LTC 4 degradation) or with (for determination f LTC 4 synthase 
activity) catalase (60 pg/ml) at 37°C for 5 min and preincubated in the 
presence or absence of PKC inhibitors (3/tM) for another 2rain, prior 
to treatment with PMA (80 nM, 30 min). Thereafter the cells were 
incubated with 600 nM LTC4 (A) or 10/IM LTA 4 (B) for 5 rain. Control 
incubations were performed in the absence of PKC inhibitors and 
PMA. Each value represents he mean of two independent experiments 
performed in duplicate. 
dase-dependent metabolism of cysteinyl leukotrienes in human 
granulocytes [13,14]. In addition, the phorbol ester provoked 
inhibition of LTC 4 synthase activity. The latter effect was dem- 
onstrated by a PMA-induced suppression of the conversion of 
LTA4 to LTC4 in granulocyte suspensions, which had been 
pretreated with catalase. Both effects were prevented by specific 
PKC inhibitors, suggesting that these actions were mediated via 
PKC activation. Moreover, the suppression of LTC4 synthase 
activity could be observed also in experiments where the cells 
were disrupted by sonication before incubation with LTA4, in 
agreement with a phosphoregulation f the enzyme. This find- 
ing also excludes the possibility that the PMA-induced attenu- 
ation of LTC4 formation was secondary to interference with 
cellular leukotriene transport. 
The present results confirm recently reported PMA-induced 
down-regulation of LTC 4 synthase activity in established 
human pre-leukemic cell lines [21,22] and demonstrate that 
similar phosphoregulatory mechanisms control LTC 4 synthase 
activity also in physiologically relevant normal granulocytes. It 
should be emphasized that granulocyte suspensions contain 
predominantly neutrophils, which lack LTC4 synthase, whereas 
LTCa-producing eosinophils constitute a minor fraction. Nev- 
ertheless, the amounts of LTC 4 produced from LTA4 in the 
presence of catalase were almost 50% of LTB4 levels in intact 
cells and similar to those of LTB 4 in disrupted granulocytes, 
demonstrating considerable LTC4-producing capacity within 
the granulocyte preparation. The possibility that contaminating 
platelets contributed substantially to this capacity can be ex- 
cluded, since the conversion of LTA4 to LTC4 in granulocyte 
suspensions was unaffected by the thromboxane analogue U- 
46619 (Sj61inder et al., unpublished observation), which induce 
down-regulation of LTC4 synthase activity in platelets [23]. 
Furthermore, the number of remaining platelets in the granulo- 
cyte suspensions was always low (see section 2). The finding 
that neutrophil LTB4 production was unaffected by treatment 
with phorbol ester excludes more unspecific effects on leuko- 
triene formation, such as interference with cellular LTA4 up- 
take. 
Exogenously added LTA4, rather than agents provoking leu- 
kotriene synthesis from endogenous ubstrate, e.g. calcium 
ionophore A23187 or fMLP, was used in the present investiga- 
tion. This was mainly because both A23187 and fMLP has been 
demonstrated to activate PKC [27,28]. Furthermore, PKC has 
been reported to increase the release of endogenous ara- 
chidonic acid via stimulation of cPLA2 [29]. Therefore, it was 
of importance to bypass PKC-dependent regulation of ara- 
chidonic acid liberation, by supplying the cells with the immedi- 
ate substrate for LTC4 synthase. 
Interestingly, pronounced ifferences in time dependence b - 
tween the two effects of PMA on leukotriene metabolism were 
observed. Thus, whereas LTC4 degradation was rapidly in- 
duced, the suppression of LTC 4 synthase was preceded by a lag 
phase and developed slowly. The reason for this discrepancy 
is presently unknown, but may indicate differences in the signal 
transduction pathways leading to the various effects. Since di- 
rect phosphoregulation of enzyme activity is usually essentially 
instant, it may be speculated that the LTC4 synthase is not the 
primary target for the phosphorylation involved in the control 
of this enzyme. Thus, phosphorylation f regulatory protein or 
PKC-dependent induction of other mechanisms leading to 
down-regulated enzyme activity may be alternative possibili- 
ties. On the other hand, LTC4 synthase has been demonstrated 
to contain two consensus sequences for PKC phosphorylation, 
indicating that the activity of the enzyme may be controlled by 
direct phosphoregulation [6,18,20]. The finding that PMA 
treatment provoked own-regulation f LTC4 synthase activity 
also in the presence of catalase contradicts the possibility that 
the enzyme inhibition is secondary to the induction of oxidative 
metabolism. The precise mechanisms behind the phosphoregu- 
latory control of LTC 4 synthase needs to be further clarified. 
In summary, the present findings indicate that phosphoregu- 
latory, PKC-dependent mechanisms are involved in the control 
of LTC 4 synthesis in normal human granulocytes, as earlier 
reported in established myeloid cell lines [21,22] and human 
platelets [23]. However, although direct activation of PKC in- 
duced attenuation of platelet LTC 4 synthase activity, receptor- 
mediated regulation of the enzyme appeared to be primarily 
dependent on the function of another protein kinase, possibly 
a tyrosine specific kinase [23]. Therefore, further investigation 
of possible receptor-mediated LTC 4 synthase regulation in my- 
eloid cells is warrented. 
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